15.08.2022 17:30

Immunoassay Market worth $49.6 billion by 2027 - Exclusive Report by MarketsandMarkets™

Folgen
Werbung

CHICAGO, Aug. 15, 2022 /PRNewswire/ -- Immunoassay Market is projected to grow from USD 40.2 billion in 2022 to USD 49.6 billion by 2027, at a CAGR of 4.3% from 2022 to 2027, according to a new report by MarketsandMarkets™, The immunoassay market is driven by increasing incidence of chronic and infectious diseases, increasing adoption of immunoassay-based POC testing and rapid testing, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing. Growth in the emerging economies and development of condition specific biomarkers and tests are expected to provide lucrative growth opportunities for the market.

MarketsandMarkets_Logo

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436

Browse in-depth TOC on "Immunoassay Market"

362 – Tables
53 – Figures
430 – Pages

The reagents & kits accounted for the largest share of the immunoassay market, by product segment, in 2021

The global market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the high consumption and repeat purchases of reagents & kits and the increasing number of immunoassay tests performed across the globe.

Rapid Tests segment to register the highest growth rate among technology during the forecast period

The immunoassay market is segmented into ELISA, rapid tests, ELISpot, western blotting, radioimmunoassays, and other technologies. Rapid tests are used to screen donated blood for HIV, HCV, HBV, and HCG antibodies. Rapid tests are effective as an aid in POC diagnosis, especially in emergency and primary care settings.

The blood segment accounted for the largest share of the immunoassay market, by specimen, in 2021

Based on specimens, the market is segmented into blood, saliva, urine, and other specimens. In 2021, blood specimens accounted for the largest share of the market, primarily due to the rising incidence of chronic and infectious diseases and increase in the rate of blood donations.

Infectious diseases segment to register the highest growth rate among applications during the forecast period

The global immunoassay market is segmented into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, and other applications. With rise in the number of products being launched for the diagnosis of infectious diseases, the segment is expected to register higher CAGR during the forecast period.

The hospitals & clinics segment accounted for the largest share of the immunoassay market, by end user, in 2021

With a rise in the prevalence of chronic and infectious diseases, along with the availability of advanced technologies has led to significant growth of the hospitals & clinics end user segment. The segment is also anticipated to register highest growth rate during the forecast period.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=436

North America is the largest regional market for immunoassay market

The global market has been segmented into five major regions—North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America. In 2021, North America dominated the global market in 2021. The large share of the North American market is primarily driven by the rising prevalence of chronic diseases, increasing geriatric population, and the presence of leading national clinical laboratories, and the easy accessibility of technologically advanced instruments.

The major players operating in this immunoassay market are Abbott Laboratories (US), and F. Hoffmann-La Roche (Switzerland), and Siemens Healthineers (Germany).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=436

Browse Adjacent Market: Medical Devices Market Research Reports & Consulting

Related Reports:

Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease (HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) (2022 - 2027)

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com  
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/immunoassay-market.asp  
Visit Our Website: https://www.marketsandmarkets.com/  
Content Source: https://www.marketsandmarkets.com/PressReleases/immunoassay.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

JETZT LIVE mit Marcel Maschmeyer!

Wie stellen Sie Ihr Depot jetzt noch krisensicher auf? Und wie generieren Sie attraktive Erträge bei vergleichsweise geringen Schwankungen? Im Online-Seminar heute um 18 Uhr verrät Ihnen ein Experten-Duo exklusive Aktienstrategien.

Werbung
Werbung
Werbung
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Zahlreiche Schwankungen: DAX schließt etwas tiefer -- ifo-Index sinkt stärker als befürchtet -- Monopolkommission äußert Bedenken wegen Uniper-Verstaatlichung -- Vonovia, Varta, VW im Fokus

IPO: Porsche Sportwagen-Aktien dürften bei Börsengang offenbar oberes Ende der Spanne erreichen. Deutscher Marktplatz verzeichnete in Corona-Krise ein schnelles Wachstum. VERBIO-Aktie: Gewinnrückgang für 2022/23 erwartet. Nord Stream 2: Gaspipeline verzeichnet Druckabfall - Mögliches Leck. Lagarde: Zinserhöhungen für die nächsten Ratssitzungen erwartet.

Umfrage

Sollte Deutschland Kampfpanzer und weitere schwere Waffen an die Ukraine zu liefern

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln